As the pioneer of AI-enabled medical devices industry in China, Keya Medical has been committed to the research, development and commercialization of AI-enabled diagnostic devices and high-value therapeutic devices, helping the intelligent upgrade of the medical industry. The "Deep Pulse Fraction DVFFR" developed by Keya Medical is the world's first CTFFR detection product using deep learning technology. With this product, Keya Medical has also become the first medical device enterprise in China with three types of certified products of artificial intelligence medical devices.
Before the birth of CTFFR detection method, pressure guide wire+catheter room was often used to detect coronary heart disease. This method is an invasive detection method, which requires the skills of operators and the health of patients. Moreover, the pressure guide wire for testing belongs to disposable consumables, and it costs about 6,543.8+0,000 yuan to use once, which also puts forward certain requirements for patients' economic ability. Therefore, this detection method has not been widely promoted in clinic.
Compared with the traditional method of measuring FFR value with pressure guide wire, the emergence of CTFFR, a noninvasive method for detecting coronary heart disease, is undoubtedly a great progress. However, the non-intelligent CTFFR detection products must also bear a huge amount of calculation and complicated operation process. It usually takes about 4 hours to get the test results.
The clinical application of intelligent noninvasive CTFFR detection product "deep pulse fraction DVFFR" completely subverts the status quo that coronary heart disease detection is a heavy work. It integrates the key technologies of artificial intelligence, medical imaging, biomedical engineering and other related disciplines, covering a number of cutting-edge deep learning algorithms independently developed by Keya Medical. It intelligently optimizes every link from medical image processing, model reconstruction to FFR calculation, improves the accuracy and robustness of segmentation and greatly improves the processing speed. It takes only about 10 minute to complete the calculation of a test sample, which greatly improves the detection efficiency of coronary heart disease.
The clinical application of intelligent noninvasive CTFFR detection product "deep pulse fraction DVFFR" not only improves the work efficiency of doctors, but also reduces the mental, physical and economic burden of patients. The clinical application of this product makes the detection of coronary heart disease enter a "rapid era", which has a positive effect on the orderly development of China's medical and health undertakings and national medical insurance undertakings.